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Electrical cardioversion of patients with atrial fibrillation (AF) is frequently performed to
relieve symptoms and improve cardiac performance. Patients undergoing cardioversion are
treated conventionally with therapeutic anticoagulation for three weeks before and four weeks
after cardioversion to decrease the risk of thromboembolism. A transesophageal echocardi-
ography (TEE)-guided strategy has been proposed as an alternative that may lower stroke and
bleeding events. Patients without atrial cavity thrombus or atrial appendage thrombus by
TEE are cardioverted on achievement of therapeutic anticoagulation, whereas cardioversion
is delayed in higher risk patients with thrombus. The aim of this review is to discuss the issues
and controversies associated with the management of patients with AF undergoing cardio-
version. We provide an overview of the TEE-guided and conventional anticoagulation
strategies in light of the recently completed Assessment of Cardioversion Using Transesoph-
ageal Echocardiography (ACUTE) clinical trial. The two management strategies comparably
lower the patient’s embolic risk when the guidelines are properly followed. The TEE-guided
strategy with shorter term anticoagulation may lower the incidence of bleeding complications
and safely expedite early cardioversion. The inherent advantages and disadvantages of both
strategies are presented. The TEE-guided approach with short-term anticoagulation is
considered to be a safe and clinically effective alternative to the conventional approach, and
it is advocated in patients in whom earlier cardioversion would be clinically beneficial. (J Am
Coll Cardiol 2001;37:691–704) © 2001 by the American College of Cardiology
Electrical cardioversion of patients with atrial fibrillation
(AF) to normal sinus rhythm is frequently performed to
relieve symptoms, improve cardiac performance and possi-
bly decrease cardioembolic risk. However, the electrical
cardioversion procedure itself has an inherent risk of stroke
due to possible embolization of pre-existing thrombus in the
left atrial appendage (1). Patients undergoing electrical
cardioversion are conventionally treated with therapeutic
anticoagulation for three weeks before and four weeks after
cardioversion to decrease this risk (2). Transesophageal
echocardiography (TEE) with short-term anticoagulation
has been proposed as an alternative strategy to guide
anticoagulation management for patients with AF under-
going electrical cardioversion (3,4). The lack of sound
clinical trial data on stroke rates, bleeding risk and health
care economics in randomized studies has fueled the con-
fusion and controversy on the relative merits of the two
strategies.
Since the early 1990s, the TEE-guided approach with
short-term anticoagulation was suggested to have several
potential advantages over the conventional management of
seven weeks of anticoagulation. First, TEE should be able
to detect left atrial appendage thrombi that are presumably
responsible for embolic stroke after electrical cardioversion.
Thus, sparing patients with thrombi from cardioversion may
reduce the incidence of embolic events. Second, in the
majority of patients without left atrial appendage thrombi,
earlier cardioversion may shorten the period of anticoagu-
lation and lower the corresponding risk of bleeding compli-
cations. The cost savings from lowered embolic and bleed-
ing rates with earlier cardioversion for patients without
thrombi may offset the cost of the TEE-guided strategy.
Finally, it was postulated that earlier cardioversion may
increase the likelihood of a successful return to and main-
tenance of sinus rhythm.
In contrast, some investigators have pointed to the
potential disadvantages of the TEE-guided strategy (5–8).
They maintain that the clinical efficacy of TEE-guided
management has not been clearly demonstrated and the cost
is not justified in the absence of efficacy data. Defenders of
conventional management further argue that small thrombi
can be missed by TEE, the TEE examination is labor
intensive and the expertise needed to detect thrombi may
not be suitable for community hospitals.
The two competing management strategies have
prompted written debate on the relative merits of the
approaches (6,9). Likewise, recent national cardiology
meetings have featured oral debates addressing the contro-
versy (10–12).
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In the absence of randomized data to guide the clinician,
the American College of Chest Physicians (ACCP) practice
guidelines (2), the American College of Cardiology/
American Heart Association (ACC/AHA) practice guide-
lines on AF (13) and the ACC/AHA echocardiography
practice guidelines (14) have suggested that the TEE-
guided approach may be an alternative to the conventional
strategy (15). Recently, the Assessment of Cardioversion
Using Transesophageal Echocardiography (ACUTE) mul-
ticenter, randomized trial of .1,200 patients (15,16) has
confirmed that this approach should be considered a strong
alternative in the early cardioversion of patients with AF.
This review addresses the issues and controversies asso-
ciated with the anticoagulation management of patients
with AF undergoing cardioversion. We discuss the basic
mechanisms of stroke after electrical cardioversion for pa-
tients with AF. We present the advantages and disadvan-
tages of the conventional and TEE-guided anticoagulation
approaches, as well as the preliminary results of the recently
completed ACUTE trial. General recommendations based
on the prevailing data are presented to guide the clinician in
the management of these patients.
Atrial fibrillation and stroke. Atrial fibrillation is the most
common sustained arrhythmia encountered in clinical prac-
tice, with an overall prevalence of 0.4% in the general
population (13,17–19), affecting 2.2 million Americans
(18,20). The prevalence of AF increases markedly with
advancing age, affecting 0.2% of the population 25 to 34
years old, 2% to 5% of those .60 years and 10% of those
.80 years (18,19,21–23). The percentage of the population
that is elderly is expected to rise over the next few decades,
thus causing an increased burden of diseases related to AF
(24,25).
One of the most important sequelae of AF is its associ-
ation with thromboembolic disease and stroke. A four- to
sixfold increase (15-fold with a history of rheumatic heart
disease) makes AF one of the most potent risk factors for
stroke in the elderly and the most common cause of embolic
stroke (19,26–29). The Framingham Heart Study and AF
trials showed an annual stroke rate of 4.2% and 4.5% per
year, respectively (29–31). The risk of stroke in nonvalvular
AF varies with age, beginning at a rate of 1.5% in the sixth
decade and increasing two- to threefold with each increas-
ing decade, reaching 24% in the ninth decade (30). Most
strokes associated with AF are presumed to be from thrombi
formed in the fibrillating left atrial appendage (32,33).
Atrial fibrillation has also been associated with a twofold
increase in both total and cardiovascular mortality (19). In
addition, the morbidity of AF appears to be substantial
(34,35). The consequences of AF include a decreased
functional capacity as a result of palpitations, fatigue,
dyspnea or signs of myocardial ischemia; congestive heart
failure; pulmonary edema; or hypotension. Functional ca-
pacity decreases in those patients in whom normal sinus
rhythm cannot be restored (34,35). The rapid ventricular
rates of AF may also impair ventricular function (36,37).
Furthermore, continued AF causes mechanical and electri-
cal remodeling. This remodeling may result in an increased
propensity for continuing or recurring AF (38).
Nonvalvular AF is responsible for .75,000 strokes an-
nually in the U.S. (28,39). Patients with AF spent an
estimated average of five days in the hospital, at a cost of
$4,800, which represents a total annual cost of $1 billion
(40). Therefore, AF has an enormous impact in the U.S. by
increasing not only the incidence of stroke and mortality,
but also medical costs, including acute hospital payments
and total-care payments (24).
Cardioversion and stroke. Since 1962, direct current
(DC) cardioversion has been used to restore sinus rhythm in
patients with AF (41). Unfortunately, electrical cardiover-
sion has a risk of clinical thromboembolism that ranges
from 0% to 5.6% (without anticoagulation), usually in the
first week after the procedure (42–67). Table 1 lists the
major studies of embolic events (since the 1960s) grouped
by either electrical or chemical cardioversion. A summary of
these studies suggests that there is little difference in the
embolic risk between electrical and chemical cardioversions
(1.4 6 1.3% vs. 1.2 6 1.0%).
A period of empiric anticoagulation before DC cardio-
version may lower the risk of embolism, as shown in 1969
(60), but because there are few prospective studies (4), the
exact rate of embolism is unknown. Notably, the 5.6% risk
of stroke in the week after cardioversion in nonanticoagu-
lated patients is similar to the yearly incidence for patients
with chronic nonvalvular AF. Thus, cardioversion increases
or concentrates the embolic risk of AF by perhaps 50-fold
during the week after the procedure.
Conventional anticoagulant strategy. Over the past de-
cade, the ACCP recommended guidelines for managing
anticoagulation around the time of cardioversion for AF
(2,26,68). These guidelines constitute current conventional
therapy and strongly recommend that all patients with AF
for more than two days be treated with warfarin for three
weeks before and continued until sinus rhythm has been
maintained for four weeks after cardioversion. Since 1992,
there has been little change in the guidelines, except that the
TEE-guided approach may be used in selected circum-
stances (2).
The rationale for conventional management is based on
Abbreviations and Acronyms
ACC 5 American College of Cardiology
AHA 5 American Heart Association
ACCP 5 American College of Chest Physicians
ACUTE 5 Assessment of Cardioversion Using
Transesophageal Echocardiography trial
AF 5 atrial fibrillation
DC 5 direct current
INR 5 international normalized ratio
TEE 5 transesophageal echocardiography
TTE 5 transthoracic echocardiography
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nonrandomized studies showing the efficacy of empiric
anticoagulation in patients undergoing electrical cardiover-
sion. The rationale for the three weeks of anticoagulation
before electrical cardioversion is based on a study suggesting
that at least 14 days are needed for fibroblastic infiltration
and stabilization of a thrombus in the left atrial appendage
(43). The four weeks of anticoagulation after cardioversion
is supported by a Doppler echocardiographic study showing
that the transmitral atrial (A) wave does not return to
normal until three to four weeks after electrical cardiover-
sion (69) and for the recurrence of AF (13).
Table 2 outlines the advantages and disadvantages of the
conventional anticoagulation approach. The major advan-
tage for the conventional strategy is that it is relatively easy
to administer and especially suitable for community hospi-
tals (13). The clinician is not dependent on the availability
of multiplane TEE probes and level III personnel well
trained in performing TEE (11). Finally, when done cor-
Table 1. Reported Incidences of Embolic Events After Electrical and Chemical Cardioversion
From Atrial Fibrillation
Study
Reference
Number n AC Rx
Percent
Embolism
Electrical cardioversion
Lown (1963) 44 50 Some 1.7
Killip (1963) 45 62 In 45% 0.0
Morris (1964) 48 70 In 6% 3.4
Oram (1964) 49 100 Some 1.9
Hurst (1964) 50 121 No 1.3
Morris (1966) 51 108 Some 2.5
Korsgren (1965) 52 138 Yes 0.0
Halmos (1966) 53 175 No 0.4
Selzer (1966) 54 189 No 2.1
Lown (1967) 55 350 In 29% 0.9
Resnekov (1967) 56 204 Some 0.6
Hall (1968) 57 142 In 39% 0.8
Radford (1968) 58 156 In 17% 0.0
Aberg (1968) 59 207 Most 0.7
Bjerkelund (1969) 60 437 Yes 1.1
McCarthy (1969) 61 149 Some 1.6
Henry (1976) 62 37 Some 5.6
Roy (1986) 63 152 In 72% 1.3
Arnold (1992) 64 454 Most 1.3
1.4 6 1.3*
Chemical cardioversion
Sokolow (1956) 42 177 Some 1.3
Goldman (1960) 43 400 No 1.5
Freeman (1963) 46 100 Yes 0.0
Rokseth (1963) 47 274 Yes 1.6
Carlsson (1996) 65 1,152 Some 0.26
Mitchell (1997) 66 110 Some 2.7
1.2 6 1.0*
*Mean value 6 SD.
AC 5 anticoagulation; Rx 5 treatment.
Table 2. Advantages and Disadvantages of the Conventional Approach to Cardioversion of
Patients With Atrial Fibrillation
Advantages Disadvantages
c Use of warfarin for 3 to 4 weeks before
cardioversion may lower the stroke rate
from 5.6% to a very low stroke rate of
, 2% (5,60,64,70).
c Delaying cardioversion to normal sinus rhythm for 3
to 4 weeks potentially decreases functional capacity
(34,35).
c Relatively easy to administer with regular
monitoring of INRs (7,13).
c Prolonging treatment for 7 to 8 weeks increases the
risk of bleeding complications (16,26,30,70–72).
c Suitable for community hospitals (7,13). c Not followed by routine clinical practice, especially in
the elderly (65,73).
c The conventional approach has withstood
the “test of time” since the 1960s.
c Patients who are at the highest risk for developing
systemic embolization who should receive more
prolonged or intensive anticoagulation are not
routinely identified (1,74).
INR 5 international normalized ratio.
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rectly (target international normalized ratio [INR] 2 to 3),
conventional management has “stood the test of time,” with
low stroke rates since the 1960s.
Unfortunately, the conventional strategy also has limita-
tions (Table 2). There have never been any controlled
studies showing its efficacy (13,14,26,40,60,64). Further-
more, anticoagulation guidelines are poorly followed in
routine clinical practice, especially in the elderly (64,65,70).
Delaying cardioversion to normal sinus rhythm for three
to four weeks may have a number of important sequelae.
Time may decrease the likelihood of successful cardiover-
sion and maintenance of normal sinus rhythm. Owing to an
ongoing atrial remodeling process, the return of atrial
function is inversely related to the duration of the atrial
arrhythmia, or “atrial fibrillation begets atrial fibrillation”
(38). In one study, patients with AF for less than two weeks
before cardioversion had a return of atrial function within
24 h, as compared with patients with AF for more than six
weeks, who had a delay in the return of atrial function up to
three weeks. An intermediate group with AF of two to six
weeks needed one week for atrial function to return (71,72).
Thus, the conventional management of anticoagulation
necessitates a delay in the return of atrial function and
increases the risk of postcardioversion thrombus formation.
Prolonging warfarin treatment for a total of seven to eight
weeks increases the risk of major and minor bleeding
complications (4,16,26,30,73–77). The period of anticoag-
ulation in conventional management almost doubles the
total duration of systemic anticoagulation, thus exposing the
patient to potentially greater bleeding complications. In
fact, cardioversion patients may be at an increased risk,
particularly during the second month of anticoagulation
(73). The major nemesis of the conventional strategy is the
need for three weeks of therapeutic anticoagulation before
cardioversion and the need to “reset the three-week time
clock” because of sub-therapeutic anticoagulation or when a
bleeding complication occurs. In fact, more than 20% of
conventional patients may never make it to electrical car-
dioversion while waiting the three weeks (4,16).
Major bleeding complications related to cardioversion
have been reported in 1% to 2% of patients, whereas minor
bleeding has been reported in 6% to 18% of patients
(4,16,72,73). These complications result in the physician
reducing the level of therapeutic anticoagulation (INR 2 to
3), thus resetting the time clock of three weeks before
cardioversion or even stopping anticoagulation. A recent
study noted that the anticoagulation ACCP guidelines are
not followed, especially in elderly patients (.65 years old)
with AF undergoing cardioversion, because of the perceived
fear of the increased risk of bleeding complications (65).
Thus, elderly patients may especially benefit from a TEE-
guided approach to cardioversion with brief anticoagulation.
Furthermore, those patients who are at high risk (i.e.,
those with left atrial cavity thrombi or left atrial appendage
thrombi) who should receive more prolonged or intensive
anticoagulation are not routinely identified before undergo-
ing the procedure (1,78).
Role of TEE in detection of thrombus. Transesophageal
echocardiography is considered the procedure of choice for
detecting left atrial appendage and left atrial cavity thrombi
(79–81) (Fig. 1). Therefore, TEE-guided cardioversion was
initially proposed as an earlier and safer alternative approach
to the conventional therapy of seven weeks of anticoagula-
tion (1,78,82).
Transesophageal echocardiography using monoplane, bi-
plane or multiplane imaging can detect thrombi in both the
left atrium and left atrial appendage, with a high degree of
sensitivity and a specificity varying from 93% to 100%
(72,81,83–88). In contrast, the less invasive transthoracic
echocardiography has not been shown to be effective in
identifying left atrial cavity or left atrial appendage thrombi
(73,89). In addition, TEE is uniquely suited to observe
spontaneous echocardiographic contrast, which is consid-
ered to be a substrate for thrombus formation (90–92) and
systemic embolization (93–95). The safety profile of TEE
has been well documented: major complication rates are
,0.02% (96,97). Therefore, many investigators have sug-
gested that patients with AF who require cardioversion can
be screened effectively for thrombus before undergoing
cardioversion. This technique may also be used to serially
monitor the resolution of thrombus in the 10% to 15% of
patients who had left atrial thrombus on the initial TEE
(81). Recently, TEE has been used to evaluate the embolic
risk potential in high and low risk patients with AF
(98–102).
Figure 1. Transesophageal echocardiographic image of a mobile and
protruding thrombus (arrow) located in the left atrial appendage of a
patient with AF scheduled to undergo DC cardioversion. Cardioversion
was postponed in this patient. AF 5 atrial fibrillation; DC 5 direct
current.
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Use of TEE does not obviate the use of anticoagulation
in cardioversion. The initial studies that used TEE in
patients undergoing electrical cardioversion attempted to
demonstrate that if thrombi could be excluded, anticoagu-
lation before and after the procedure would not be necessary
(33,103). The rationale for this earlier TEE strategy was
based on the notion that the only potential source of
thromboembolism was a pre-existing cardiac thrombus that
may embolize after successful cardioversion (43).
In subsequent investigations, TEE was used to assess the
events surrounding cardioversion (the presumed precipitat-
ing event for thromboembolism) by performing TEE both
immediately before and after the procedure (104,105).
Interestingly, left atrial appendage function declined and
spontaneous echocardiographic contrast increased (it devel-
oped or intensified in 35% of patients) from before to after
cardioversion (104) (Fig. 2). In fact, Stoddard et al. (106)
demonstrated in one patient that thrombi can indeed form
in the postcardioversion period. This deterioration of func-
tion may be independent of the mode of cardioversion
employed, and postconversion dysfunction may occur with
spontaneous (107), pharmacologic (108) or internal cardio-
version (109). A recent study suggested that thrombogenic
potential may be influenced by the duration of AF, with
brief-duration AF showing only minimal atrial stunning
(110). These findings suggested that a thrombogenic milieu
is created as a result of the cardioversion from AF (to a lesser
degree in atrial flutter [111]) to sinus rhythm and implied
that thromboembolic events can occur in the absence of an
existing or precardioversion thrombus.
Black et al. (112) compiled a series of 17 cases of
thromboembolic events occurring after a negative TEE
study for thrombus. All 17 of these patients had events
relatively soon after cardioversion, and all were subthera-
peutically anticoagulated. At the time of the embolic event,
three patients had AF for less than seven days. This series
dispelled many beliefs, including: 1) TEE can preclude the
need for anticoagulation; 2) events occur primarily in
patients with long-duration AF; and 3) all events occur
secondary to existing thrombi. The study gave credence to
the alternative mechanism for thrombogenesis and embo-
lism after cardioversion and cast doubt on the ability of
TEE to obviate the need for anticoagulation after cardio-
version. A recent review of pooled studies from the pub-
lished data showed that embolic events were more common
using TEE without anticoagulation as compared with
anticoagulation (5). These data suggest the need to antico-
agulate all patients with AF of more than two days duration,
including patients with a negative TEE for thrombus. From
these important seminal studies, it can be concluded that the
role of TEE is to enable early cardioversion without
prolonged precardioversion anticoagulation in low risk pa-
tients and to identify high risk patients with thrombi in
whom cardioversion should be postponed.
TEE-guided cardioversion with short-term anticoagula-
tion. Given the current understanding of the mechanisms
involved in thrombogenesis and embolism after cardiover-
sion of AF, many investigators have argued that using both
TEE and short-term anticoagulation could be the most
clinically rational, convenient and possibly cost-effective
strategy (1,78,101). The theoretic basis for this strategy
addresses both potential thromboembolic mechanisms, in-
cluding the existing thrombus in the left atrium or atrial
appendage, and the second mechanism, which involves an
increased potential for thrombogenesis secondary to dimin-
ished left atrial appendage function (104,105). The TEE-
guided strategy includes screening for existing thrombus
and therapeutic anticoagulation at the time of TEE, as well
as continued antithrombotic therapy to reduce the postcar-
dioversion thromboembolic mechanism. Patients identified
with left atrial cavity thrombi or left atrial appendage
thrombi by TEE may have the cardioversion procedure
postponed to allow at least three weeks of anticoagulation in
order to stabilize the thrombus. In addition, antithrombotic
therapy at the time of TEE and for four weeks after
cardioversion reduces the risk of thrombus soon after
cardioversion.
Clinical data to support the TEE-guided strategy have
emerged over the last decade in nearly 2,000 patients from
both nonrandomized and randomized studies. Table 3
shows that in the analysis of multiple randomized and
nonrandomized studies on TEE-guided cardioversion, the
Figure 2. Precardioversion (left) and postcardioversion (right) images of the left atrial appendage (LAA) using TEE. After DC cardioversion, left atrial
appendage function diminishes and spontaneous echocardiographic contrast intensifies. DC 5 direct current; LA 5 left atrium; LV 5 left ventricle; TEE 5
transesophageal echocardiography. (Reprinted with permission from the American College of Cardiology, 1994.)
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cardioversion-related embolic event rate is very low (0.35%
[7 of 1,996 patients]) (4,16,103,113–116).
Nonrandomized studies. An important nonrandomized
study (3) showed that early cardioversion after TEE could
be performed when atrial thrombi were excluded. These
investigators studied 230 patients with TEE before cardio-
version of AF and detected atrial thrombi in 34 patients
(15%). No clinically apparent embolic events were detected
after cardioversion in 186 (95%) of 196 patients in whom no
atrial thrombi were detected and who were spared long-
term anticoagulation before cardioversion as a result of a
negative TEE study for thrombus. In a more recent study of
466 patients by the same investigators (114), thrombi were
detected in 13.9%, and 88% of the patients without thrombi
were converted successfully to sinus rhythm. However, one
patient (0.2%) who had been converted to sinus rhythm
with relatively low risk had a peripheral embolus six days
after cardioversion. If the duration of AF was less than three
weeks, patients undergoing TEE-guided cardioversion were
less likely to have recurrent AF and were able to maintain
sinus rhythm at one year, as compared with patients with
AF longer than three weeks (81% vs. 60%; p 5 0.005)
(114). Other investigators (106,116) have described similar
promising results in nonrandomized patients undergoing a
TEE-guided strategy.
Randomized studies. The ACUTE pilot study was the
first prospective, randomized study of 126 patients with AF
for longer than two days duration undergoing cardioversion
(4). Patients from 10 international clinical sites were ran-
domized to either a TEE-guided strategy with brief anti-
coagulation (n 5 62) or the conventional anticoagulation
approach (n 5 64). The primary end point events were
ischemic stroke, transient ischemic attack and systemic
embolization for a four-week postcardioversion period. The
feasibility, safety and other outcomes of the ACUTE pilot
study are summarized in Table 4.
This pilot study demonstrated that a TEE-guided strat-
egy was both feasible and safe as compared with conven-
tional therapy (4). The TEE-guided strategy allowed early
cardioversion without embolization in 100% of the patients
without thrombi on TEE. Atrial thrombi were detected in
seven patients (13%), leading to postponement of electrical
cardioversion. Notably, cardioversion was done much earlier
with the TEE-guided strategy than with the conventional
strategy (0.6 weeks vs. 4.7 weeks), which highlights the
issue of time (4.7 weeks) that is needed to achieve a
therapeutic INR before cardioversion. Accordingly, the
incidence of clinical instability and bleeding tended to be
less in the TEE-guided group (1.6% vs. 7.8%; p 5 0.21).
The ACUTE multicenter trial. The ACUTE multicenter
study was a randomized clinical trial involving patients
undergoing electrical cardioversion of AF lasting longer
than two days. The study compared a TEE-guided strategy
combined with short-term anticoagulation with a conven-
tional anticoagulation strategy (15) (Fig. 3).
The study was an investigator-initiated trial lacking
principal sponsorship. The termination before enrolling the
target 3,000 patients was determined by the Data Safety and
Table 3. Summary of Studies of Transesophageal
Echocardiography (TEE)-Guided Approach to Cardioversion of
Atrial Fibrillation, Including the Incidence of Thrombus by
TEE and Recorded Embolic Events
Study
Reference
Number n
Atrial
Thrombi
Embolic
Events
Orsinelli (1993) 103 39 9 (23%) 1 (2.56%)
Stoddard (1995) 113 206 37 (18%) 0
Klein (1997) 4 126 7 (13%) 0
Weigner (1998) 114 466 64 (13.9%) 1 (0.21%)
Grimm (1998) 115 417 28 (7%) 0
Corrado (1999) 116 123 11 (9%) 0
ACUTE (2000) 16 619 79 (13.6%) 5 (0.81%)
Total 1,996 235 (11.8%) 7 (0.35%)
ACUTE 5 Assessment of Cardioversion Using Transesophageal Echocardiography.
Table 4. Feasibility and Safety Outcome Summary for the ACUTE Pilot Study by Treatment Group
TEE-Guided Approach Conventional Approach p Value
Feasibility outcomes
Electrical cardioversion 76% (47/62) (CI 63–86%) 58% (37/64) (CI 45–70%) 0.03
Scheduled electrical cardioversion 94% (44/47) (CI 58–82%) 70% (26/37) (CI 29–54%) , 0.01
Time from enrollment to electrical cardioversion (weeks) 0.6 (CI 0.3–0.9) 4.8 (CI 3.8–5.7) , 0.01
Time from enrollment to normal sinus rhythm (weeks) 1.0 (CI 0.5–1.6) 4.3 (CI 3.0–5.6) , 0.01
Safety outcomes
Embolic event 0% (CI 0–5%) 2% (1/64) (CI 0–8%) . 0.20
Cardioversion related death 0% (CI 0–5%) 0% (0/64) (CI 0–5%) . 0.20
Hemodynamic instability and bleeding 2% (CI 0–8%) 8% (5/64) (CI 3–17%) . 0.20
Other outcomes
Patients with TEE-detected RA or LA thrombi 13% (CI 5–24%) — — —
Patients without thrombus by TEE and converted to
normal sinus rhythm
75% (CI 62–86%) — — —
Normal sinus rhythm after DCC 85% (CI 51–76%) 76% (28/37) (CI 31–57%) . 0.20
Normal sinus rhythm at 8 weeks 55% (CI 42–68%) 56% (37/64) (CI 43–69%) . 0.20
Time from enrollment to follow-up (weeks) 5.7 (CI 5.1–63) 7.7 (CI 7.1–8.2) , 0.01
Data are presented as percentage (n) (95% confidence interval [CI]) or mean value (95% CI).
DCC 5 direct current cardioversion; LA 5 left atrial; RA 5 right atrial; TEE 5 transesophageal echocardiography.
Reprinted with permission from the American College of Physicians, 1997.
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Monitoring Board and the ACUTE Steering Committee,
which reported low event rates and slow recruitment. A
total of 1,222 patients were randomized from 70 clinical
international sites over a five-year period. The eight-week
study outcomes of the ACUTE study were presented
recently as a late-breaking trial at the ACC’s 2000 Scientific
Sessions (16,117).
Of the 1,222 randomized patients, 619 were assigned to
the TEE-guided arm, whereas 603 were assigned to the
conventional arm. Left or right atrial cavity and atrial
appendage thrombi were detected by TEE in 76 patients
(14%), resulting in postponement of the cardioversion. The
TEE-guided strategy allowed early (mean three days) suc-
cessful cardioversion in 81% of the patients without
thrombi. There were two patients with embolic events
occurring within the first week after cardioversion, which
were associated with AF recurrence and subtherapeutic
INRs (16,117).
Of the 603 patients assigned to the conventional arm,
only 333 (55%) had electrical cardioversion (mean 31 days)
and 80% were successful. There was one patient who had an
embolic stroke occurring within the first week after cardio-
version. Of the 270 patients who never underwent electrical
cardioversion, the main reason in 127 patients (47%) was
spontaneous or chemical conversion. In contrast, 143 pa-
tients never had cardioversion, for other reasons, including
major or minor bleeding, medical reasons and lost to
follow-up. There were also 32 patients (5%) who crossed
over to the TEE arm because of hemodynamic instability
(hypotension or congestive heart failure) (16).
In the ACUTE study, using intention-to-treat analysis
there was no difference in the composite end point of stroke,
transient ischemic attack and peripheral embolism between
the TEE-guided arm and the conventional arms (0.81% vs.
0.50%; p 5 0.50). However, there was a significant differ-
ence in the composite end point of major and minor
bleeding between the TEE-guided arm and the conven-
tional arms (2.9% vs. 5.5%; p 5 0.02) (16).
An important unexpected outcome of the ACUTE mul-
ticenter study was that it showed that the aggregate embolic
event rate for both arms of the study was much lower than
expected (0.7%), and the aggregate composite hemorrhagic
complication rate was higher than expected (4.2%). Com-
pared with the conventional strategy, the TEE-guided arm
with short-term anticoagulation decreased the composite
rate for major and minor bleeding complications. However,
there was no significant difference in 8-week maintenance of
normal sinus rhythm, cardiac deaths or cardioversion-
related deaths between the two arms. The results of this
randomized study suggested that the TEE-guided approach
with short-term anticoagulation may be considered as a
clinically effective alternative to the conventional anticoag-
ulation strategy in the management of patients undergoing
cardioversion (16,117).
Registry of patients undergoing TEE-guided cardiover-
sion. The ACUTE registry is a nonrandomized cohort of
patients with AF from the Cleveland Clinic who underwent
TEE-guided cardioversion and were followed for evidence
of stroke. In a recent review of the registry (115), atrial
thrombi were detected and cardioversion was postponed in
Figure 3. Protocol design of the ACUTE multicenter study. Enrolled patients are randomly assigned to either the TEE-guided group or the conventional
group for an eight-week study period. (Reprinted with permission from Excerpta Medica, Inc., 1998.) ACUTE 5 Assessment of Cardioversion Using
Transesophageal Echocardiography; DCC5 direct current cardioversion; TEE 5 transesophageal echocardiography.
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28 (7%) of the 417 patients. In contrast, cardioversion was
performed in 388 patients (93%), 363 (94%) of whom were
successfully converted to normal sinus rhythm without
embolic stroke (115). These results, using the TEE-guided
(ACUTE) approach, have now been extended to over 600
consecutive patients.
Cost-effectiveness. In the absence of published studies
showing the relative clinical effectiveness of the two strate-
gies, cost-effectiveness may affect patterns of use. Using a
decision analytic model, Seto et al. (118) assessed the
cost-effectiveness of the TEE-guided strategy in hospital-
ized patients with AF. The cost per quality-adjusted life year
was compared for three different management strategies: 1)
the conventional strategy with initial screening by trans-
thoracic echocardiography (TTE); 2) initial TTE, followed
by TEE and early cardioversion if an atrial thrombus is
excluded by TEE; and 3) initial TEE, followed by early
cardioversion if no atrial thrombus is detected. The TEE-
guided early cardioversion without TTE was the least costly.
Recently, they have extended their model and showed that
it was less costly to perform follow-up TEE to document
thrombus resolution for patients with thrombi on their
initial TEE (119).
Atrial thrombus resolution after prolonged cardiover-
sion. Table 5 shows a number studies using serial TEE
evaluation to document the resolution of thrombi after the
initial TEE (4,106,116,120–122) for these high risk pa-
tients. The mechanism for reduction of embolic risk using
anticoagulant agents was thought to be organization and
adherence of the thrombus to the left atrial appendage wall,
but these TEE studies support atrial thrombus resolution
and prevention of new thrombus (4,116,120). The percent-
age of thrombi resolved after three to four weeks of
anticoagulant therapy has varied widely, from 89% resolu-
tion in one study (120) to 50% in the ACUTE pilot study
(4) to 5% in another study (106). In a recent follow-up TEE
study of 164 patients with left atrial thrombi, thrombus
resolution occurred in 80% of the patients at a mean of 6.7
weeks, with little further resolution on subsequent TEE
studies (122). These discrepant findings among different
studies may relate to several factors, including different
patient characteristics, duration of AF and diagnostic crite-
ria for thrombus detection. In addition, the finding of
thrombus portends a poor outcome, with a risk of stroke or
embolic events of 10.4% per year or a death risk of 15.8%
(123). Thus, there are many unresolved issues with regard to
management of residual thrombus detected by TEE.
Discrepancy of thrombus detection and thromboembo-
lism. There remains an inconsistency between the finding
of thrombus by TEE in 10% to 15% of the patients with AF
undergoing cardioversion and stroke rates ,1% after car-
dioversion (1,4,76). There are several explanations for this
discrepancy: 1) most thrombi do not embolize and may be
related to the characteristics and location of the thrombus in
the left atrial appendage; 2) not all thromboembolic events
are clinically apparent; and 3) some appendage thrombi
detected by TEE represent false positive findings. More
investigation is needed to determine the relationship be-
tween thrombi by TEE and cardioversion-related embolic
events.
Prediction of success of conversion to normal sinus
rhythm. Initially, there was a lot of enthusiasm about the
use of left atrial appendage areas and flow velocities by
pulsed wave Doppler echocardiography to predict the im-
mediate and long-term success of cardioversion (1). How-
ever, the results have been variable to date (124–128). In
one study (124), the left atrial appendage flow velocities
(mean emptying velocity .19 cm/s), maximal left atrial
appendage area and duration of AF were useful in predict-
ing the initial recovery of sinus rhythm. However, another
study showed that the left atrial appendage flow velocities
(mean peak left atrial appendage emptying velocity .35
cm/s) were not predictive of either the success of cardiover-
sion or the maintenance of sinus rhythm at one-year
follow-up (126). Thus, the overall data suggest that a
reduced peak left atrial appendage velocity (generally ,20
cm/s) may play some role in predicting the decreased success
of cardioversion and maintenance of normal sinus rhythm,
but its unique contribution remains unknown.
Disadvantages of the TEE-guided strategy. In the con-
text of the findings of the ACUTE multicenter study and
nonrandomized studies in nearly 2,000 patients, as dis-
cussed earlier, the TEE-guided approach with short-term
anticoagulation appears to be as feasible and safe as the
conventional arm. However, there remain some important
disadvantages of using the TEE-guided approach (Table 6).
The ability of the TEE-guided strategy, as compared with
the conventional approach, to lower the stroke rate has not
Table 5. Previous Studies Documenting Resolution of Atrial Thrombus by Serial
Transesophageal Echocardiography
Study
(Reference no.) n
Frequency of
Thrombus
Anticoagulation
Duration
Atrial Thrombus
Resolved on
Second TEE
Stoddard 1995 (106) 21 NA 5 to 17 weeks 9/21 (43%)
Collins 1995 (120) 18 NA 4 weeks (median) 16/18 (89%)
Tsai 1997 (121) 8 10% NA 6/8 (75%)
Klein 1997 (4) 7 13% 6 weeks 3/7 (43%)
Jaber 2000 (122) 164 NA 6.7 weeks (mean) 131/164 (80%)
Corrado 1999 (116) 11 11% 4 weeks (median) 9/11 (82%)
NA 5 not available; TEE 5 transesophageal echocardiography.
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been shown (5–7,9,16,129). It has been largely assumed that
detecting a left atrial appendage thrombus and not cardio-
verting the patient would avoid an embolic event. Because
the embolic stroke rate was low (0.7%) (16), a subsequent
clinical trial would require .10,000 patients for adequate
statistical power (15). Using this line of reasoning, one may
argue that stroke after cardioversion is so rare; therefore,
why bother to spend the resources to detect thrombi
(6,7,11)? Another argument is that the bleeding risk reduc-
tion with the TEE-guided arm has been exaggerated.
Although TEE-guided management cuts the time of anti-
coagulation in half, Landefeld (130) has shown that the
highest risk for major bleeding is in the first three to four
weeks of outpatient warfarin therapy, which is common to
both strategies. Furthermore, often patients will need anti-
coagulation beyond the seven- to eight-week cardioversion
period, because they may have some of the important risk
factors for stroke (7) or they may have recurrent AF in the
first three to six months after cardioversion (131–134).
Also, some investigators have argued that the additional
cost of the TEE procedure is not justified in the absence of
strong efficacy data. It is estimated from industry sources
that between $50 and $100 million is spent on TEE for
patients with AF, without guidelines or criteria for these
patients (135). Despite models showing potential cost-
effectiveness (118), the preliminary ACUTE cost data on
the TEE-guided arm do not appear to be statistically
different from the data on the conventional arm. The
TEE-guided strategy may potentially be more costly than
the conventional approach because of the increased costs
associated with repeating TEE after four weeks of antico-
agulation (119).
Despite the sensitivity of multiplane TEE being .95%,
TEE may miss thrombi ,2 mm, which may have the
potential to embolize, especially in the setting of the
complex morphology of multilobed appendage (136). In
contrast, with the increasing use of TEE in the community,
there may be a tendency for overcalling thrombi (false
positive results) in the left atrial appendage. It may be
difficult to distinguish thrombi from artifacts, pectinate
muscles and severe spontaneous echocardiographic contrast,
or “sludge,” in the left atrial appendage (15,137). Figure 4
provides examples of some of the echocardiographic pitfalls
in the recognition of left atrial appendage thrombus.
Another important issue is whether the TEE-guided
strategy is suitable for community hospitals, where equip-
ment and personnel resources as well as expertise (level III
echocardiographers) may be limited (138,139). Transesoph-
ageal echocardiography is a semi-invasive technique with a
potential for esophageal perforation (96,97).
National use of TEE-guided strategy. There is a growing
perception that the use of the TEE-guided approach is
increasing nationally. We lack actual Medicare data, and
therefore national health statistics are not yet known.
Murray et al. (140) performed a survey of 197 clinical
practices in the U.S. to evaluate national use of this strategy.
The survey revealed that the frequency of the TEE-guided
strategy varies within institutions from 0% to 80%, with the
highest concentration in tertiary-care institutions and uni-
versity hospitals. Overall, the TEE-guided procedure was
being used at least occasionally in 75% of the institutions
surveyed and may account for ;12% of all electrical cardio-
versions for AF (140). At our own institution, the TEE-
guided approach has remained relatively stable, accounting
for 14.7% of the 3,329 electrical cardioversions from 1991 to
1997 (140). More recently, TEE-guided cardioversions
Table 6. Advantages and Disadvantages of the Transesophageal Echocardiography
(TEE)-Guided Approach to Cardioversion of Patients With Atrial Fibrillation
Undergoing Cardioversion
Advantages Disadvantages
c Transesophageal echocardiography should be
able to detect left atrial appendage thrombi,
which increase the risk of embolic stroke
after electrical cardioversion. Thus, sparing
patients with thrombi from cardioversion
may reduce the incidence of embolic events.
c Transesophageal echocardiography is performed
without any definite guidelines about who
should receive the procedure (high risk vs. low
risk) (12).
c In the majority of patients with left atrial
appendage thrombi, earlier cardioversion
may shorten the period of anticoagulation
and lower the corresponding risk of bleeding
complications (16,117).
c Residual thrombus on repeat TEE may
diminish the cost-effectiveness of the TEE-
guided approach (119).
c A TEE-guided approach may prove more
cost-effective owing to the reduction in
laboratory monitoring costs and the
reduction in bleeding complications.
c Transesophageal echocardiography requires a
level III–trained physician and availability of
expensive echocardiographic machines.
c Earlier cardioversion is believed to increase
the likelihood of a successful return to and
maintenance of sinus rhythm (4).
c Transesophageal echocardiography may miss
thrombi that may embolize after cardioversion
(6). In contrast, TEE may render false positive
results by erroneously identifying spontaneous
echocardiographic contrast, “sludge,” multilobed
appendages or pectinate muscles as thrombus.
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have increased dramatically at our institution and now
exceed 29% of all electrical cardioversions performed.
Status of TEE-guided strategy in 2001. The current data
suggest that the TEE-guided strategy with short-term
anticoagulation is a strong alternative to the conventional
strategy (16,141). Clearly, with stroke rates ,1.0%, the
clinician can utilize either management strategy in their
daily practices, depending on the individual patient or
physician requirements. For example, the clinician at the
community hospital may not have the resources or TEE
skills (level III) to perform the TEE-guided approach and
may elect to follow the conventional guidelines. In contrast,
the hospital-based clinician may tend to perform the TEE-
guided strategy more often, because skilled personnel and
the infrastructure are readily available.
From the available evidence, there are certain patient
subgroups that may benefit from the TEE-guided strategy.
First, the inpatient with new-onset AF (,4 weeks dura-
tion), regardless of risk profile, may benefit from early
cardioversion using the TEE-guided strategy. This may be
particularly important for high risk patients (such as those
with congestive heart failure, previous embolism or hemo-
dynamic instability) in whom the prompt return of normal
sinus rhythm would be beneficial (142). Second, the high-
risk patient may benefit from further risk stratification by
TEE to identify left atrial appendage thrombus, severe
spontaneous echocardiographic contrast or complex ather-
oma (143,144). The identification of a thrombus before
cardioversion would lead to cancellation of the cardioversion
and more prolonged (and perhaps intense) anticoagulant
therapy. A repeat TEE would be necessary to show throm-
bus resolution before cardioversion. Third, even for patients
in whom the likelihood of thrombus is low (100), eliminat-
ing the need for prolonged anticoagulation pre-cardioversion
by ruling out the presence of thrombus would allow early
cardioversion and avoid the delay for return to sinus rhythm.
We await further data for the intermediate risk patient in
whom the detection rate of thrombus is not well described.
Fourth, the inpatient would be better suited to have the
TEE-guided approach with intravenous heparin, as com-
Figure 4. Pitfalls in TEE screening for thrombi using the TEE-guided approach to cardioversion, including pectinate muscles (arrows) in the left atrial
appendage (A), multilobed appendage (arrows) (B) and viscous spontaneous echocardiographic contrast, or “sludge” (C). Pectinate muscle tissue, multilobed
appendage or sludge can be mistaken for thrombi, rendering a false positive TEE screening result. TEE 5 transesophageal echocardiography.
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pared with the outpatient. The outpatient setting has some
limitations, because these patients would need three to five
days of warfarin before the TEE-guided DC cardioversion,
and thus the time benefit of early cardioversion is dimin-
ished (4,7,31). Outpatient management may be improved
with the use of low molecular weight heparin, which can be
used as bridge therapy to warfarin (see later discussion)
(145). Finally, the benefit of the TEE-guided strategy
seems to be limited in the chronically anticoagulated patient
with persistent AF undergoing cardioversion.
New developments. A major limitation of the TEE-
guided approach with intravenous heparin (for inpatients) is
the extended length of the hospital stay to allow for overlap
between the heparin and warfarin (four to five days).
Recently, a newer TEE-guided strategy has been advocated
with the use of low molecular weight heparin therapy to be
used as bridge therapy for anticoagulation. This therapy has
the potential to lower costs by treating patients as outpa-
tients instead of inpatients (146), provide greater patient
convenience and increase quality of life, as compared with
intravenous heparin. A randomized clinical pilot study
(ACUTE II) is under way to compare TEE-guided cardio-
version using low molecular weight heparin with the stan-
dard intravenous unfractionated heparin in patients with AF
(145). Recently, a TEE-stratified study was able to identify
162 low risk patients with AF and atrial flutter lasting
longer than two days and safely perform immediate cardio-
version with the use of low molecular weight heparin
(dalteparin) to bridge warfarin therapy (147). The low risk
patients receiving immediate cardioversion maintained sinus
rhythm better after one month, as compared with the
patients with prolonged precardioversion warfarin therapy.
In addition, there is work in progress involving direct
thrombin inhibitors and glycoprotein IIa/IIIb antiplatelet
therapy for thrombotic prophylaxis of patients with AF.
There is also growing interest in the use of chemical
cardioversion with ibutilide or dofetilide and TEE-guided
cardioversion of AF (148,149).
CONCLUSIONS
There remains an ongoing controversy about the manage-
ment of patients with AF undergoing cardioversion. The
standard of care is still conventional management, which is
performed by most cardiologists worldwide. Based on the
findings of both nonrandomized and randomized studies,
the TEE-guided approach with short-term anticoagulation
can be considered a safe and clinically effective alternative to
conventional management, especially for patients who may
benefit from early cardioversion.
Acknowledgments
The authors wish to thank Susan E. Jasper, BSN, Ariel
Goodman-Bizon, BA, and Marie D. Campbell for their
assistance in the preparation of this manuscript.
Reprint requests and correspondence: Dr. Allan L. Klein, The
Cleveland Clinic Foundation, 9500 Euclid Avenue, Department
of Cardiology/Desk F-15, Cleveland, Ohio 44195. E-mail:
kleina@ccf.org.
REFERENCES
1. Grimm RA, Stewart WJ, Black IW, Thomas JD, Klein AL. Should
all patients undergo transesophageal echocardiography before electri-
cal cardioversion of atrial fibrillation? J Am Coll Cardiol 1994;23:
533–41.
2. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE.
Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579S–
89S.
3. Manning WJ, Silverman DI, Keighley CS, Oettgen P, Douglas PS.
Transesophageal echocardiographically facilitated early cardioversion
from atrial fibrillation using short-term anticoagulation: final results
of a prospective 4.5-year study. J Am Coll Cardiol 1995;25:1354–61.
4. Klein AL, Grimm RA, Black IW, et al. Cardioversion guided by
transesophageal echocardiography: the ACUTE pilot study—a ran-
domized, controlled trial. Ann Intern Med 1997;126:200–9.
5. Moreyra E, Finkelhor RS, Cebul RD. Limitations of transesophageal
echocardiography in the risk assessment of patients before nonanti-
coagulated cardioversion from atrial fibrillation and flutter: an anal-
ysis of pooled trials. Am Heart J 1995;129:71–5.
6. Prystowsky EN. Management of atrial fibrillation: simplicity sur-
rounded by controversy. Ann Intern Med 1997;126:244–6.
7. Prystowsky EN. Perspectives and controversies in atrial fibrillation.
Am J Cardiol 1998;82:3I–6I.
8. Autore C, Cartoni D, Piccininno M. Multiplane transesophageal
echocardiography and stroke. Am J Cardiol 1998;81:79G–81G.
9. Klein AL, Murray RD, Grimm RA. Transesophageal echocar-
diography-guided cardioversion: going for broke? Ann Intern Med
1997;127:652–3.
10. Klein A, Gersh B. Should TEE be done routinely before cardiover-
sion (debate). Presented at the American Society of Echocardiogra-
phy Scientific Sessions; Chicago, IL: 2000.
11. Klein AL, Prystowsky EN. All patients with new-onset atrial
fibrillation should undergo TEE prior to cardioversion (debate).
Presented at the American College of Cardiology 47th Annual
Scientific Session, Atlanta, Georgia, 1998.
12. Manning WJ, Gersh B. TEE-guided cardioversion should be the
routine approach; protagonist/antagonist (debate). Presented at the
American Heart Association Scientific Sessions, Dallas, Texas, 1998.
13. Prystowsky EN, Benson DW, Fuster V, et al. Management of
patients with atrial fibrillation: A statement for healthcare profes-
sionals from the subcommittee on electrocardiography and electro-
physiology, American Heart Association. Circulation 1996;93:1262–
77.
14. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guide-
lines for the clinical application of echocardiography: executive
summary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines (Committee on
Clinical Application of Echocardiography). J Am Coll Cardiol
1997;29:862–79.
15. ACUTE Investigators. Design of a clinical trial for the assessment of
cardioversion using transesophageal echocardiography (ACUTE
multicenter study). Am J Cardiol 1998;81:877–83.
16. ACUTE Investigators. Assessment of Cardioversion Using Trans-
esophageal Echocardiography (ACUTE) multicenter study: eight-
week clinical outcomes. Presented at the American College of
Cardiology Scientific Sessions, Late-Breaking Clinical Trial, 2000.
17. Ostrander L, Brandt RL, Kjelsberg M, et al. Electrocardiographic
findings among the adult population of a total natural community—
Tecumseh, Michigan. Circulation 1965;31:888–98.
18. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG.
Prevalence, age distribution, and gender of patients with atrial
fibrillation: analysis and implications. Arch Intern Med 1995;155:
469–73.
19. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary
heart disease and atrial fibrillation: the Framingham study. Am
Heart J 1983;106:389–96.
701JACC Vol. 37, No. 3, 2001 Klein et al.
March 1, 2001:691–704 TEE-Guided Cardioversion
20. Blackshear JL, Kopecky SL, Litin SC, Safford RE, Hammill SC.
Management of atrial fibrillation in adults: prevention of thrombo-
embolism and symptomatic treatment. Mayo Clin Proc 1996;71:
150–60.
21. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemio-
logic features of chronic atrial fibrillation: the Framingham study.
N Engl J Med 1982;306:1018–22.
22. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation: risk of
stroke and role of antithrombotic therapy. Circulation 1991;84:469–
81.
23. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE,
Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects
(the Cardiovascular Health Study). Am J Cardiol 1994;74:236–41.
24. Wolf PA. Prevention of stroke. Lancet 1998;352 Suppl 3:SIII15–8.
25. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB.
Impact of atrial fibrillation on mortality, stroke and medical costs.
Arch Intern Med 1998;158:229–34.
26. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A.
Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S–
9S.
27. Wolf PA, Dawber TR, Thomas HJ, Kannel WB. Epidemiologic
assessment of chronic atrial fibrillation and risk of stroke: the
Framingham study. Neurology 1978;28:973–7.
28. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major
contributor to stroke in the elderly. The Framingham Study. Arch
Intern Med 1987;147:1561–4.
29. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an indepen-
dent risk factor for stroke: the Framingham study. Stroke 1991;22:
983–8.
30. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of
antithrombotic therapy in atrial fibrillation: analysis of pooled data
from five randomized controlled trials. Arch Intern Med 1994;154:
1449–57.
31. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial
fibrillation. JAMA 1999;281:1830–5.
32. Rittoo D, Sutherland G, Currie P, Starkey I, Shaw T. A prospective
study of left atrial spontaneous echo contrast and thrombus in 100
consecutive patients referred for balloon dilation of the mitral valve.
J Am Soc Echocardiogr 1994;7:516–27.
33. Black IW, Hopkins AP, Lee LC, Walsh WF. Evaluation of
transesophageal echocardiography before cardioversion of atrial fibril-
lation and flutter in nonanticoagulated patients. Am Heart J 1993;
126:375–81.
34. Gosselink AT, Crijns HJ, van den Berg MP, et al. Functional
capacity before and after cardioversion of atrial fibrillation: a con-
trolled study. Br Heart J 1994;72:161–6.
35. Gosselink AT, Bijlsma EB, Landsman ML, Crijns HJ, Lie KI.
Long-term effect of cardioversion on peak oxygen consumption in
chronic atrial fibrillation: a 2-year follow-up. Eur Heart J 1994;15:
1368–72.
36. Grogan M, Smith H, Gersh B, Wood D. Left ventricular dysfunc-
tion due to atrial fibrillation in patients initially believed to have
idiopathic dilated cardiomyopathy. Eur Heart J 1992;69:1570–3.
37. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick
AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a re-
view of animal models and clinical studies. J Am Coll Cardiol
1997;29:709–15.
38. Wijffels M, Kirchhof C, Dorland R, Allessie M. Atrial fibrillation
begets atrial fibrillation: a study in awake chronically instrumented
goats. Circulation 1995;92:1954–68.
39. SPAF Investigators. Stroke Prevention in Atrial Fibrillation (SPAF)
study: final results. Circulation 1991;84:527–39.
40. Nattel S. Newer developments in the management of atrial fibrilla-
tion. Am Heart J 1995;130:1094–106.
41. Lown B, Amarasingham R, Neuman J. New method for terminating
cardiac arrhythmias. JAMA 1962;182:548–55.
42. Sokolow M, Ball RE. Factors influencing conversion of chronic atrial
fibrillation with specific reference to serum quinidine concentration.
Circulation 1956;14:568–85.
43. Goldman MJ. The management of chronic atrial fibrillation. Prog
Cardiovasc Dis 1960;2:465–79.
44. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. “Cardiover-
sion” of atrial fibrillation: a report on the treatment of 65 episodes in
50 patients. N Engl J Med 1963;269:325–31.
45. Killip T, Baer RA. Hemodynamic effects after reversion from atrial
fibrillation to sinus rhythm by precordial shock. J Clin Invest
1966;45:658–71.
46. Freeman I, Wexler J. Atrial fibrillation: anticoagulation and quinidi-
nization. South Med J 1967;60:13–7.
47. Rokseth R, Storstein Q. Quinidine therapy of chronic auricular
fibrillation: the occurrence and mechanism of syncope. Arch Intern
Med 1963;111:184–9.
48. Morris JJ, Peter RH, McIntosh HD, Kong Y, North WC. Experi-
ence with cardioversion of atrial fibrillation and flutter. Am J Cardiol
1964;14:94–100.
49. Oram S, Davies JPH. Further experience of electrical conversion of
atrial fibrillation to sinus rhythm: analysis of 100 patients. Lancet
1964;1:1294–8.
50. Hurst JW, Paulk EA Jr, Proctor HD, et al. Management of patients
with atrial fibrillation. Am J Med 1964;37:728–41.
51. Morris JJ, Peter RH, McIntosh HD. Electrical conversion of atrial
fibrillation: immediate and long-term results and selection of pa-
tients. Ann Intern Med 1966;65:216–31.
52. Korsgren M, Leskinen E, Peterhoff V, et al. Conversion of atrial
arrhythmias with DC shock: primary results and a follow-up inves-
tigation. Acta Med Scand 1965;177 Suppl 431:1–40.
53. Halmos PB. Direct current cardioversion of atrial fibrillation. Br
Heart J 1966;28:302–8.
54. Selzer A, Kelly JJ, Johnson RB, et al. Immediate and long-term
results of electrical conversion of arrhythmias. Prog Cardiovasc Dis
1966;9:90–104.
55. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J
1967;29:469–89.
56. Resnekov L. Haemodynamic studies before and after electrical
conversion of atrial fibrillation and flutter to sinus rhythm. Br Heart J
1967;29:700–8.
57. Hall JI, Wood DR. Factors affecting cardioversion of atrial arrhyth-
mias with special reference to quinidine. Br Heart J 1968;30:84–90.
58. Radford MD, Evans DW. Long-term results of DC reversion of
atrial fibrillation. Br Heart J 1968;30:91–6.
59. Aberg H, Cullhed I. Direct current conversion of atrial fibrillation:
long-term results. Acta Med Scand 1968;184:433–40.
60. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in
preventing embolism related to DC electrical conversion of atrial
fibrillation. Am J Cardiol 1969;23:208–16.
61. McCarthy C, Varghese PJ, Barritt DW. Prognosis of atrial arrhyth-
mias treated by electrical counter shock therapy: a three-year follow-
up. Br Heart J 1969;31:496–500.
62. Henry WL, Morganroth J, Pearlman AS, et al. Relation between
echocardiographically determined left atrial size and atrial fibrillation.
Circulation 1976;53:273–9.
63. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of
anticoagulant therapy in the prevention of embolic complications of
atrial fibrillation. Am Heart J 1986;112:1039–43.
64. Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role
of prophylactic anticoagulation for direct current cardioversion in
patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol
1992;19:851–5.
65. Carlsson J, Tebbe U, Rox J, et al. Cardioversion of atrial fibrillation
in the elderly. Am J Cardiol 1996;78:1380–4.
66. Mitchell MA, Hughes GS, Ellenbogen KA, et al. Cardioversion
related stroke rates in atrial fibrillation and atrial flutter. Circulation
1997;96 Suppl I:I453.
67. Johnston SD, Trouton TG, Wilson C. A review of direct current
cardioversions for atrial arrhythmia. Ulster Med J 1998;67:19–24.
68. Laupacis A, Albers G, Dunn M, Feinberg W. Antithrombotic
therapy in atrial fibrillation: third ACCP Conference on Antithrom-
botic Therapy. Chest 1992;102:426S–53S.
69. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler
evaluation of atrial mechanical function after electrical cardioversion
of atrial fibrillation. J Am Coll Cardiol 1989;13:617–23.
70. Schlicht JR, Davis RC, Naqi K, Cooper W, Rao BV. Physician
practices regarding anticoagulation and cardioversion of atrial fibril-
lation. Arch Intern Med 1996;156:290–4.
71. Manning WJ, Silverman DI, Katz SE, et al. Temporal dependence of
the return of atrial mechanical function on the mode of cardioversion
of atrial fibrillation to sinus rhythm. Am J Cardiol 1995;75:624–6.
72. Silverman DI, Manning WJ. Role of echocardiography in patients
702 Klein et al. JACC Vol. 37, No. 3, 2001
TEE-Guided Cardioversion March 1, 2001:691–704
undergoing elective cardioversion of atrial fibrillation. Circulation
1998;98:479–86.
73. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial
fibrillation. Am J Cardiol 1989;63:745–6.
74. Forfar J. A 7-year analysis of haemorrhage in patients on long term
anticoagulant treatment. Br Heart J 1979;42:128–32.
75. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C.
Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am
Coll Cardiol 1991;18:349–55.
76. Levine MN, Raskob G, Hirsch J. Hemorrhagic complications of
long-term anticoagulant therapy. Chest 1989;95 Suppl:36–5.
77. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic compli-
cations of anticoagulant treatment. Chest 1995;108:276S–90S.
78. Leung DY, Grimm RA, Klein AL. Transesophageal echocardiog-
raphy-guided approach to cardioversion of atrial fibrillation. Prog
Cardiovasc Dis 1996;39:21–32.
79. Mugge A, Kuhn H, Daniel WG. The role of transesophageal
echocardiography in the detection of left atrial thrombi. Echocardi-
ography 1993;10:405–17.
80. Mugge A, Kuhn H, Nikutta P, Grote J, Lopez JA, Daniel WG.
Assessment of left atrial appendage function by biplane transesoph-
ageal echocardiography in patients with nonrheumatic atrial fibrilla-
tion: identification of a subgroup of patients at increased embolic risk.
J Am Coll Cardiol 1994;23:599–607.
81. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of
transesophageal echocardiography for identifying left atrial thrombi.
Ann Intern Med 1995;123:817–22.
82. Manning WJ. Atrial fibrillation, transesophageal echo, electrical
cardioversion, and anticoagulation. Clin Cardiol 1995;18:122–8.
83. Aschenberg W, Schlulter M, Kremer P, Schroder E, Siglow V,
Bleifeld W. Transesophageal two-dimensional echocardiography for
the detection of left atrial appendage thrombus. J Am Coll Cardiol
1986;7:163–6.
84. Mugge A, Daniel WG, Hausmann J, Godke J, Wagenbreth L,
Lichtlen PR. Diagnosis of left atrial appendage thrombi by trans-
esophageal echocardiography: clinical implications and follow-up.
Am J Card Imaging 1990;4:173–9.
85. Acar J, Michel PL, Cormier B, Vahanian A, Iung B. Features of
patients with severe mitral stenosis with respect to atrial rhythm:
atrial fibrillation in predominant and tight mitral stenosis. Acta
Cardiol 1992;47:115–24.
86. Olson JD, Goldenberg IF, Pedersen W, et al. Exclusion of atrial
thrombus by transesophageal echocardiography. J Am Soc Echocar-
diogr 1992;5:52–6.
87. Hwang JJ, Chen JJ, Lin SC, et al. Diagnostic accuracy of left atrial
appendage thrombi by transesophageal echocardiography for detect-
ing left atrial thrombi in patients with rheumatic heart disease having
undergone mitral valve operations. Am J Cardiol 1993;72:677–81.
88. Fatkin D, Scalia G, Jacobs N, et al. Accuracy of biplane transesoph-
ageal echocardiography in detecting left atrial thrombus. Am J
Cardiol 1996;77:321–3.
89. Schweizer P, Bardos P, Erbel R, et al. Detection of left atrial thrombi
by echocardiography. Br Heart J 1981;45:148–56.
90. Beppu S, Nimura Y, Sakakibara H, Nagata S, Park YD, Izumi S.
Smoke-like echo in the left atrial cavity in mitral valve disease: its
features and significance. J Am Coll Cardiol 1985;6:744–9.
91. Iliceto S, Antonelli G, Sorino M, Biasco G, Rizzon P. Dynamic
intracavitary left atrial echoes in mitral stenosis. Am J Cardiol
1985;55:603–6.
92. Daniel WG, Nellessen U, Schroder E, et al. Left atrial spontaneous
contrast in mitral valve disease: an indicator for increased thrombo-
embolic risk. J Am Coll Cardiol 1988;11:1204–11.
93. Erbel R, Stern H, Ehrenthal W, et al. Detection of spontaneous
echocardiographic contrast within the left atrium by transesophageal
echocardiography: spontaneous echocardiographic contrast. Clin
Cardiol 1986;9:245–52.
94. Black IW, Hopkins AP, Lee LC, Walsh WF. Left atrial spontaneous
echo contrast: a clinical and echocardiographic analysis. J Am Coll
Cardiol 1991;18:398–404.
95. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF.
Prognostic implications of left atrial spontaneous echo contrast in
nonvalvular atrial fibrillation. J Am Coll Cardiol 1994;24:755–62.
96. Daniel WG, Erbel R, Kasper W, et al. Safety of transesophageal
echocardiography: a multicenter survey of 10,419 examinations.
Circulation 1991;83:817–21.
97. Khandheira B, Seward J, Tajik A. Transesophageal echocardiogra-
phy. Mayo Clin Proc 1994;69:856–63.
98. Stollberger C, Chnupa P, Kronik G, et al. Transesophageal echocar-
diography to assess embolic risk in patients with atrial fibrillation.
ELAT study group, Embolism in Left Atrial Thrombi. Ann Intern
Med 1998;128:630–8.
99. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW,
Hart RG, the Stroke Prevention in Atrial Fibrillation III Investiga-
tors. Transesophageal echocardiographic correlates of clinical risk of
thromboembolism in nonvalvular atrial fibrillation. J Am Coll Car-
diol 1998;31:1622–6.
100. The SPAF III Writing Committee for the Stroke Prevention in
Atrial Fibrillation Investigators. Patients with nonvalvular atrial
fibrillation at low risk of stroke during treatment with aspirin: the
Stroke Prevention in Atrial Fibrillation III study. JAMA 1998;279:
1273–7.
101. Main ML, Klein AL. Cardioversion in atrial fibrillation: indications,
thromboembolic prophylaxis, and role of transesophageal echocardi-
ography. J Thromb Thrombolysis 1999;7:53–60.
102. Blackshear JL, Zabalgoitia M, Pennock G, et al., the Stroke
Prevention and Atrial Fibrillation Transesophageal Echocardiogra-
phy Investigators. Warfarin safety and efficacy in patients with
thoracic aortic plaque and atrial fibrillation. Am J Cardiol 1999;83:
453–5.
103. Orsinelli DA, Pearson AC. Usefulness of transesophageal echocar-
diography to screen for left atrial thrombus before elective cardiover-
sion for atrial fibrillation. Am J Cardiol 1993;72:1337–9.
104. Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical
cardioversion for atrial fibrillation on left atrial appendage function
and spontaneous echo contrast: characterization by simultaneous
transesophageal echocardiography. J Am Coll Cardiol 1993;22:
1359–66.
105. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesopha-
geal echocardiography before and during direct current cardioversion
of atrial fibrillation: evidence for “atrial stunning” as a mechanism of
thromboembolic complications. J Am Coll Cardiol 1994;23:307–16.
106. Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesoph-
ageal echocardiographic guidance of cardioversion in patients with
atrial fibrillation. Am Heart J 1995;129:1204–15.
107. Grimm RA, Leung DY, Black IW, Stewart WJ, Thomas JD, Klein
AL. Left atrial appendage “stunning” after spontaneous conversion of
atrial fibrillation demonstrated by transesophageal Doppler echocar-
diography. Am Heart J 1995;130:174–6.
108. Falcone RA, Morady F, Armstrong WF. Transesophageal echocar-
diographic evaluation of left atrial appendage function and sponta-
neous contrast formation after chemical or electrical cardioversion of
atrial fibrillation. Am J Cardiol 1996;78:435–9.
109. Omran H, Jung W, Rabahieh R, et al. Left atrial chamber and
appendage function after internal atrial defibrillation: a prospective
and serial transesophageal echocardiographic study. J Am Coll
Cardiol 1997;29:131–8.
110. Sparks PB, Jayaprakash S, Mond HG, Vohra JK, Grigg LE, Kalman
JM. Left atrial mechanical function after brief duration atrial fibril-
lation. J Am Coll Cardiol 1999;33:342–9.
111. Grimm RA, Stewart WJ, Thomas JD, Klein AL. Left atrial append-
age “stunning” following electrical cardioversion of atrial flutter: an
attenuated response as compared to atrial fibrillation as a mechanism
for a lower susceptibility to thromboembolic events. J Am Coll
Cardiol 1997;29:582–9.
112. Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by
transesophageal echocardiography does not preclude embolism after
cardioversion of atrial fibrillation: a multicenter study. Circulation
1994;89:2509–13.
113. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial
appendage thrombus is not uncommon in patients with acute atrial
fibrillation and a recent embolic event: a transesophageal echocardio-
graphic study. J Am Coll Cardiol 1995;25:452–9.
114. Weigner MJ, Patel U, Thomas LR, et al. Transesophageal echocar-
diography facilitated cardioversion from atrial fibrillation: short-term
safety and implications regarding maintenance of sinus rhythm
(abstr). Circulation 1998;98 Suppl I:I500.
115. Grimm RA, Agler DA, Vaughn SE, et al. TEE-guided anticoagu-
703JACC Vol. 37, No. 3, 2001 Klein et al.
March 1, 2001:691–704 TEE-Guided Cardioversion
lation in patients undergoing electrical cardioversion of atrial fibril-
lation: results from the ACUTE Registry (abstr). J Am Coll Cardiol
1998;31 Suppl:353A.
116. Corrado G, Tadeo G, Beretta S, et al. Atrial thrombi resolution after
prolonged anticoagulation in patients with atrial fibrillation. Chest
1999;115:140–3.
117. Kleiman NS, Califf RM. Results from late-breaking clinical trial
sessions at ACCIS 2000 and ACC 2000. J Am Coll Cardiol
2000;36:310–25.
118. Seto TB, Taira DA, Tsevat J, Manning WJ. Cost-effectiveness of
transesophageal echocardiographic-guided cardioversion: a decision
analytic model for patients admitted to the hospital with atrial
fibrillation. J Am Coll Cardiol 1997;29:122–30.
119. Seto TB, Taira DA, Manning WJ. Cardioversion in patients with
atrial fibrillation and left atrial thrombi on initial transesophageal
echocardiography: should transesophageal echocardiography be re-
peated before elective cardioversion? A cost-effectiveness analysis.
J Am Soc Echocardiogr 1999;12:508–16.
120. Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion
of nonrheumatic atrial fibrillation: reduced thromboembolic compli-
cations with four weeks of precardioversion anticoagulation are
related to atrial thrombus resolution. Circulation 1995;92:160–3.
121. Tsai LM, Lin LJ, Teng JK, Chen JH. Prevalence and clinical
significance of left atrial thrombus in nonrheumatic atrial fibrillation.
Int J Cardiol 1997;58:163–9.
122. Jaber WA, Prior DL, Thamilarasan M, et al. Efficacy of anticoagu-
lation in resolving left atrial and left atrial appendage thrombi: a
transesophageal echocardiographic study. Am Heart J 2000;140:
150–6.
123. Leung DY, Davidson PM, Cranney GB, Walsh WF. Thromboem-
bolic risks of left atrial thrombus detected by transesophageal echo-
cardiogram. Am J Cardiol 1997;79:626–9.
124. Manabe K, Oki T, Tabata T, et al. Transesophageal echocardio-
graphic prediction of initially successful electrical cardioversion of
isolated atrial fibrillation: effects of left atrial appendage function. Jpn
Heart J 1997;38:487–95.
125. Omran H, Jung W, Schimpf R, et al. Echocardiographic parameters
for predicting maintenance of sinus rhythm after internal atrial
defibrillation. Am J Cardiol 1998;81:1446–9.
126. Perez Y, Duval AM, Carville C, et al. Is left atrial appendage flow a
predictor for outcome of cardioversion of nonvalvular atrial fibrilla-
tion? A transthoracic and transesophageal echocardiographic study.
Am Heart J 1997;134:745–51.
127. Verhorst PM, Kamp O, Welling RC, Van Eenige MJ, Visser CA.
Transesophageal echocardiographic predictors for maintenance of
sinus rhythm after electrical cardioversion of atrial fibrillation. Am J
Cardiol 1997;79:1355–9.
128. Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardio-
graphic assessment of the left atrial appendage. J Am Coll Cardiol
1999;34:1867–77.
129. Chambers J. Is it safe to cardiovert atrial fibrillation without antico-
agulation if the transesophageal echocardiogram is normal? Intern
J Cardiol 1998;63:107–9.
130. Landefeld C, Goldman L. Major bleeding in outpatients treated with
warfarin: incidence and prediction by factors known at the start of
outpatient therapy. Am J Med 1989;87:144–52.
131. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and
maintenance of sinus rhythm and indications for anticoagulation
therapy. Ann Intern Med 1996;125:311–23.
132. Arnar DO, Danielsen R. Factors predicting maintenance of sinus
rhythm after direct current cardioversion of atrial fibrillation and
flutter: a reanalysis with recently acquired data. Cardiology 1996;87:
181–8.
133. Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial
fibrillation: success of serial cardioversion therapy and safety of oral
anticoagulation. Arch Intern Med 1996;156:2585–92.
134. Tieleman RG, Van Gelder I, Crijns H, et al. Early recurrence of
atrial fibrillation after electrical cardioversion: a result of fibrillation-
induced electrical remodeling of the atria? J Am Coll Cardiol
1998;3:167–73.
135. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a
decade of progress in stroke prevention. Ann Intern Med 1999;13:
688–95.
136. Veinot JP, Harrity PJ, Gentile F, et al. Anatomy of the normal left
atrial appendage: a quantitative study of age-related changes in 500
autopsy hearts—implications for echocardiographic examination.
Circulation 1997;96:3112–5.
137. Murray RD, Bashir M, Jasper SE, Grimm RA, et al. Left atrial
appendage “sludge” in atrial fibrillation patients undergoing TEE
screening for cardioversion: the ACUTE registry (abstr). J Am Soc
Echocardiogr 2000;13:445.
138. Pearlman AS, Gardin J, Martin R, et al. Guidelines for physician
training in transesophageal echocardiography: recommendations of
the American Society of Echocardiography Committee for Physician
Training in Echocardiography. J Am Soc Echocardiogr 1992;5:187–
94.
139. Stewart WJ, Aurigemma GP, Bierman FZ, et al. Guidelines for
training in adult cardiovascular medicine. Core cardiology training
symposium. Task force 4: training in echocardiography. J Am Coll
Cardiol 1995;25:16–9.
140. Murray RD, Goodman A, Lieber E, et al. National use of the
transesophageal echocardiographic-guided approach to cardioversion
for patients in atrial fibrillation. Am J Cardiol 2000;85:239–44.
141. Klein AL. Emerging role of echocardiography in the evaluation of
patients with atrial fibrillation into the new millennium. Echocar-
diogr 2000;17:353–6.
142. Gersh BJ. Antithrombotic therapy in nonrheumatic/nonvalvular
atrial fibrillation. J Cardiovasc Electrophysiol 1999;10:461–71.
143. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators,
Committee on Echocardiography. Transesophageal echocardio-
graphic correlates of thromboembolism in high-risk patients with
nonvalvular atrial fibrillation. Ann Intern Med 1998;128:639–47.
144. Manning WJ, Douglas PS. Transesophageal echocardiography and
atrial fibrillation: added value or expensive toy? Ann Intern Med
1998;128:685–7.
145. Murray RD, Shah A, Jasper S, et al. Transesophageal echocardiog-
raphy-guided enoxaparin antithrombotic strategy for cardioversion of
atrial fibrillation: the ACUTE II pilot study. Am Heart J 2000;139:
e5.
146. Murray RD, Deitcher SR, Shah A, et al. Potential clinical efficacy
and cost benefit of a TEE-guided low molecular weight heparin
(enoxaparin) approach to antithrombotic therapy in patients under-
going immediate cardioversion from atrial fibrillation. J Am Soc
Echocardiogr 2001. In press.
147. Roijer A, Eskilsson J, Olssen B. Transesophageal echocardiography-
guided cardioversion of atrial fibrillation or flutter: selection of a
low-risk group for immediate cardioversion. Eur Heart J 2000;21:
837–47.
148. Murray KT. Ibutilide. Circulation 1998;97:493–7.
149. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide
in patients with congestive heart failure and left ventricular dysfunc-
tion. Danish Investigators of arrhythmia and mortality on dofetilide
study group. N Engl J Med 1999;341:857–65.
704 Klein et al. JACC Vol. 37, No. 3, 2001
TEE-Guided Cardioversion March 1, 2001:691–704
